Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC) at a specific stage, based on tissue or cell sample testing
• People who have already received a standard first-line treatment for advanced or metastatic NSCLC, as outlined in the trial protocol
• People who have received a platinum-based chemotherapy combination at some point in their treatment, unless there is a documented medical reason why this was not appropriate
• People who have tumour tissue available (either previously stored or newly collected) that can be tested for a specific protein called MUC16
• People who have at least one tumour that can be measured using a CT or MRI scan, including tumours in areas that were previously treated with radiation if there is scan-confirmed evidence the disease has grown there
• People whose general health and ability to carry out daily activities falls within a certain range, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)

Who may not be able to join:

• People whose cancer got worse within 84 days of starting their first immunotherapy treatment targeting PD-1 or PD-L1
• People still experiencing side effects from a previous cancer treatment that have not reduced to a mild level, with some exceptions such as hair loss, hearing loss, mild nerve-related symptoms, or hormone-related conditions being managed with replacement therapy
• People who have untreated or currently active brain tumours, cancer that has spread to the brain or spinal fluid, or spinal cord compression
• People who are currently taking part in, or who have received an experimental treatment in another clinical study within the 4 weeks before the planned start of this trial
• People who have received an immunotherapy drug targeting PD-1 or PD-L1 within 21 days before the planned first dose in this trial
• People who have received other types of anti-cancer immunotherapy within 21 days before the planned first dose
• People who have received chemotherapy drugs that destroy cancer cells within 21 days before the planned first dose
• People who have received a specific type of targeted therapy called an anti-EGFR antibody within a timeframe that depends on the specific drug used (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.